The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

Enthorin has signed an option-to-license deal with Rumi to advance ENT-7340 for FXS, as well as other intellectual and developmental disabilities.

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.

This week's podcast features the Clinical Trials Arena team and GlobalData analysts who discuss the biggest study readouts from the ESMO Congress 2026.

Gameto’s lead asset is a cell-based IVM tool, Fertilo, which is currently in late-stage development within the US.

The FDA has granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, to treat retinitis pigmentosa.

Pathos AI has secured $237m in a Series E round to expand its clinical oncology pipeline and scale its AI drug development platform.

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.

Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

British biotech generally raised more across public and private markets in Q3 2026, despite an overall downturn in the flow of VC more generally into the UK.

Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes ...